10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2014 | |||
Consolidated Statement of Earnings | |||
Period Ending Dec 31, 2014 10-K (Filed: Feb 27, 2015) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | |
| Net Sales | $ 20,247 | 19,657 | 19,050 |
| Cost of products sold, excluding amortization of intangible assets | 9,218 | 9,193 | 8,899 |
| Amortization of intangible assets | 555 | 588 | 595 |
| Research and development | 1,345 | 1,371 | 1,461 |
| Selling, general and administrative | 6,530 | 6,372 | 6,735 |
| Total Operating Cost and Expenses | 17,648 | 17,524 | 17,690 |
| Operating Earnings | 2,599 | 2,133 | 1,360 |
| Interest expense | 150 | 145 | 320 |
| Interest income | (77) | (67) | (59) |
| Net loss on extinguishment of debt | 18 | 1,351 | |
| Net foreign exchange (gain) loss | (24) | 46 | (31) |
| Other (income) expense, net | 14 | (32) | (1) |
| Earnings (loss) from Continuing Operations before Taxes | 2,518 | 2,041 | (220) |
| Taxes on Earnings (loss) from Continuing Operations | 797 | 53 | (457) |
| Earnings from Continuing Operations | 1,721 | 1,988 | 237 |
| Earnings from Discontinued Operations, net of taxes | 563 | 588 | 5,726 |
| Net Earnings | 2,284 | 2,576 | 5,963 |
| Basic Earnings Per Common Share | |||
| Continuing Operations (in dollars per share) | 1.13 | 1.27 | 0.15 |
| Discontinued Operations (in dollars per share) | 0.37 | 0.37 | 3.61 |
| Net Earnings (in dollars per share) | 1.50 | 1.64 | 3.76 |
| Diluted Earnings Per Common Share | |||
| Continuing Operations (in dollars per share) | 1.12 | 1.26 | 0.15 |
| Discontinued Operations (in dollars per share) | 0.37 | 0.36 | 3.57 |
| Net Earnings (in dollars per share) | 1.49 | 1.62 | 3.72 |
| Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) | 1,516 | 1,558 | 1,575 |
| Dilutive Common Stock Options and Awards (in shares) | 11 | 16 | 17 |
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options and Awards (in shares) | 1,527 | 1,574 | 1,592 |
| Outstanding Common Stock Options Having No Dilutive Effect (in shares) | 1 | 1 | 1 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2014 | |||
Consolidated Statement of Comprehensive Income | |||
Period Ending Dec 31, 2014 10-K (Filed: Feb 27, 2015) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | |
| Net Earnings | $ 2,284 | 2,576 | 5,963 |
| Less: Earnings from Discontinued Operations | 563 | 588 | 5,726 |
| Earnings from Continuing Operations | 1,721 | 1,988 | 237 |
| Foreign currency translation gain (loss) adjustments | (2,206) | (239) | (7) |
| Net actuarial gains (losses) and prior service cost and credits and amortization of net actuarial losses and prior service cost and credits, net of taxes of $(459) in 2014, $393 in 2013 and $(276) in 2012 | (917) | 882 | (865) |
| Unrealized gains (losses) on marketable equity securities, net of taxes of $(7) in 2014 and $(10) in 2013 and ($4) in 2012 | (12) | (18) | (7) |
| Net gains (losses)on derivative instruments designated as cash flow hedges, net of taxes of $24 in 2014, $(13) in 2013 and $(29) in 2012 | 94 | (53) | (118) |
| Other Comprehensive Income (Loss) | (3,041) | 572 | (997) |
| Comprehensive Income (Loss) | (757) | 3,148 | 4,966 |
| Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax as of December 31: | |||
| Cumulative foreign currency translation (loss) adjustments | (2,924) | (718) | (79) |
| Net actuarial (losses) and prior service (cost) and credits | (2,229) | (1,312) | (3,596) |
| Cumulative unrealized gains on marketable equity securities | 1 | 13 | 31 |
| Cumulative gains on derivative instruments designated as cash flow hedges | 99 | 5 | 50 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2014 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2014 10-K (Filed: Feb 27, 2015) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | |
| Cash Flow From (Used in) Operating Activities: | |||
| Net earnings | $ 2,284 | 2,576 | 5,963 |
| Adjustments to reconcile net earnings to net cash from operating activities - | |||
| Depreciation | 918 | 928 | 1,363 |
| Amortization of intangible assets | 630 | 791 | 1,419 |
| Share-based compensation | 246 | 262 | 433 |
| Acquired in-process and collaborations research and development | 288 | ||
| Investing and financing (gains) losses, net | 69 | 4 | 356 |
| Net loss on extinguishment of debt | 18 | 1,351 | |
| Trade receivables | (195) | (113) | 36 |
| Inventories | (297) | (154) | (417) |
| Prepaid expenses and other assets | 30 | 131 | (35) |
| Trade accounts payable and other liabilities | (225) | (436) | (134) |
| Income taxes | 197 | (665) | (1,309) |
| Net Cash From Operating Activities | 3,675 | 3,324 | 9,314 |
| Cash Flow From (Used in) Investing Activities: | |||
| Acquisitions of property and equipment | (1,077) | (1,145) | (1,795) |
| Acquisitions of businesses and technology, net of cash acquired | (3,317) | (580) | (706) |
| Purchases of investment securities | (1,507) | (10,064) | (11,998) |
| Proceeds from sales of investment securities | 5,624 | 7,839 | 8,936 |
| Other | 75 | 21 | 3 |
| Net Cash (Used in) Investing Activities | (202) | (3,929) | (5,560) |
| Cash Flow From (Used in) Financing Activities: | |||
| Proceeds from issuance of (repayments of) short-term debt and other | 1,343 | 2,086 | 784 |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 9 | 14,700 | |
| Repayments of long-term debt and debt with maturities over 3 months | (577) | (303) | (11,071) |
| Acquisition and contingent consideration payments related to business acquisitions | (400) | (495) | (521) |
| Transfer of cash and cash equivalents to AbbVie Inc. | (5,901) | ||
| Purchases of common shares | (2,195) | (1,605) | (2,364) |
| Proceeds from stock options exercised, including income tax benefit | 429 | 395 | 1,850 |
| Dividends paid | (1,342) | (882) | (3,183) |
| Net Cash (Used in) Financing Activities | (2,742) | (6,696) | 195 |
| Effect of exchange rate changes on cash and cash equivalents | (143) | (26) | 40 |
| Net Decrease (Increase) in Cash and Cash Equivalents | 588 | (7,327) | 3,989 |
| Cash and Cash Equivalents, Beginning of Year | 3,475 | 10,802 | |
| Cash and Cash Equivalents, End of Period | 4,063 | 3,475 | 10,802 |
| Supplemental Cash Flow Information: | |||
| Income taxes paid | 448 | 1,039 | 1,367 |
| Interest paid | 182 | 148 | 576 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
ABBOTT LABORATORIES | ||
Ticker: ABT Fiscal Year: 2014 | ||
Consolidated Balance Sheet | ||
Period Ending Dec 31, 2014 10-K (Filed: Feb 27, 2015) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2014 | Dec 31, 2013 | |
| Assets | ||
| Current Assets: | ||
| Cash and cash equivalents | $ 4,063 | 3,475 |
| Investments, primarily bank time deposits and U.S. treasury bills | 397 | 4,623 |
| Trade receivables, less allowances of - 2014: $310; 2013: $312 | 3,586 | 3,986 |
| Inventories: | ||
| Finished products | 1,807 | 1,866 |
| Work in process | 278 | 349 |
| Materials | 558 | 478 |
| Total inventories | 2,643 | 2,693 |
| Deferred income taxes | 1,705 | 2,528 |
| Other prepaid expenses and receivables | 1,975 | 1,504 |
| Current assets held for disposition | 892 | 438 |
| Total Current Assets | 15,261 | 19,247 |
| Investments | 229 | 119 |
| Property and Equipment, at Cost: | ||
| Land | 457 | 502 |
| Buildings | 2,968 | 2,994 |
| Equipment | 8,480 | 8,506 |
| Construction in progress | 727 | 868 |
| Property and Equipment, at cost | 12,632 | 12,870 |
| Less: accumulated depreciation and amortization | 6,697 | 6,965 |
| Net property and equipment | 5,935 | 5,905 |
| Intangible assets, net of amortization | 6,198 | 5,735 |
| Goodwill | 10,067 | 9,772 |
| Deferred income taxes and other assets | 1,651 | 2,109 |
| Non-current assets held for disposition | 1,934 | 66 |
| Total Assets | 41,275 | 42,953 |
| Liabilities and Shareholders' Investment | ||
| Current Liabilities: | ||
| Short-term borrowings | 4,382 | 3,164 |
| Trade accounts payable | 1,064 | 1,026 |
| Salaries, wages and commissions | 776 | 906 |
| Other accrued liabilities | 2,943 | 3,500 |
| Dividends payable | 362 | 341 |
| Income taxes payable | 270 | 175 |
| Current portion of long-term debt | 55 | 9 |
| Current liabilities held for disposition | 680 | 386 |
| Total Current Liabilities | 10,532 | 9,507 |
| Long-term debt | 3,408 | 3,388 |
| Post-employment Obligations and other long - term Liabilities | 5,588 | 4,784 |
| Non-current liabilities held for disposition | 108 | 7 |
| Commitments and Contingencies | ||
| Shareholders' Investment: | ||
| Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued | ||
| Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2014: 1,694,929,949; 2013: 1,685,827,096 | 12,383 | 12,048 |
| Common shares held in treasury, at cost - Shares: 2014: 186,894,515; 2013: 137,728,810 | (8,678) | (6,844) |
| Earnings employed in the business | 22,874 | 21,979 |
| Accumulated other comprehensive income (loss) | (5,053) | (2,012) |
| Total Abbott Shareholders' Investment | 21,526 | 25,171 |
| Noncontrolling Interests in Subsidiaries | 113 | 96 |
| Total Shareholders' Investment | 21,639 | 25,267 |
| Total Liabilities and Shareholders' Investment | 41,275 | 42,953 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2014 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |